Key result
Intrameningeal injection of convalescent poliomyelitis serum prevented the development of paralytic experimental disease in monkeys when administered 18 to 24 hours after intracerebral virus injection.
Why the study?
Does convalescent poliomyelitis serum prevent paralytic experimental disease in monkeys inoculated with poliomyelitis virus?
Does convalescent poliomyelitis serum prevent paralytic experimental disease in monkeys inoculated with poliomyelitis virus?
Convalescent serum, but not normal serum, prevents the development of paralytic poliomyelitis in monkey models when administered early after viral exposure.
No takes yet. Share an insight, caveat, or question.
Does not support clinical use; hypothesis-generating for human poliomyelitis prevention trials.
Simon Flexner (1928) studied Poliomyelitis. Convalescent poliomyelitis serum vs. Normal serum was evaluated on Development of paralytic experimental disease. Intrameningeal injection of convalescent poliomyelitis serum prevented the development of paralytic experimental disease in monkeys when administered 18 to 24 hours after intracerebral virus injection.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: